HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- fluoro- N- (4- fluorophenyl)- 4- hydroxy- N- (4- hydroxyphenyl)benzamide

an estrogen receptor alpha agonist

Also Known As:

GTx-758

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Belkoff, Laurence: 2 articles (12/2020 - 02/2015)
2.	Getzenberg, Robert H: 2 articles (12/2020 - 02/2015)
3.	Hancock, Michael L: 2 articles (12/2020 - 02/2015)
4.	Tutrone, Ronald: 2 articles (12/2020 - 02/2015)
5.	Yu, Evan Y: 2 articles (12/2020 - 02/2015)
6.	Coss, Christopher C: 2 articles (02/2015 - 03/2012)
7.	Dalton, James T: 2 articles (02/2015 - 03/2012)
8.	Steiner, Mitchell S: 2 articles (02/2015 - 03/2012)
9.	Aronson, William: 1 article (12/2020)
10.	Flaig, Thomas: 1 article (12/2020)

Related Diseases

1.	Hot Flashes 12/01/2020 - "GTx-758 resulted in a reduction in hot flashes. " 02/01/2015 - "GTx-758 led to fewer hot flashes, decreases in bone turnover markers, and alterations in IGF-1 compared with leuprolide. " 03/01/2012 - "The present studies show that orally administered GTx-758 reversibly suppressed testosterone to castrate levels and subsequently reduced prostate volume and circulating prostate-specific antigen in relevant preclinical models without inducing hot flashes, bone loss, thrombophilia, hypercoagulation, or increasing fat mass." 02/01/2015 - "GTx-758 reduced estrogen deficiency side effects of hot flashes, bone loss, and insulin resistance but with a higher incidence of VTEs. "
2.	Prostatic Neoplasms (Prostate Cancer) 08/01/2014 - "Prostate cancer: GTx-758 reduces testosterone." 12/01/2020 - "Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer." 02/01/2015 - "Hormone-naive advanced prostate cancer patients were randomized to oral GTx-758 1000 mg/d, 2000 mg/d, or leuprolide depot. " 02/01/2015 - "Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer."
3.	Thrombophilia 03/01/2012 - "The present studies show that orally administered GTx-758 reversibly suppressed testosterone to castrate levels and subsequently reduced prostate volume and circulating prostate-specific antigen in relevant preclinical models without inducing hot flashes, bone loss, thrombophilia, hypercoagulation, or increasing fat mass."
4.	Insulin Resistance 02/01/2015 - "GTx-758 reduced estrogen deficiency side effects of hot flashes, bone loss, and insulin resistance but with a higher incidence of VTEs. "

Related Drugs and Biologics

1.	Testosterone (Sustanon)
2.	Estrogen Receptor alpha
3.	Prostate-Specific Antigen (Semenogelase)
4.	Leuprolide (Lupron)
5.	Insulin-Like Growth Factor I (IGF-1)
6.	Hormones (Hormone)
7.	Estrogens (Estrogen)
8.	Androgens
9.	vinyltriethoxysilane (VTES)

Related Therapies and Procedures

1.	Castration
2.	Therapeutics